Willow Medical Leadership and Credentials: What You Need to Know

What Is Willow and How Does Its Model Work?

Willow operates as a direct-to-consumer telehealth platform offering GLP-1 receptor agonist prescriptions and women's hormonal health services on a cash-pay basis, bypassing traditional insurance networks. Patients complete an online intake, consult asynchronously or synchronously with an assigned clinician, and receive prescriptions shipped directly or fulfilled through a partner pharmacy. Cash-pay telehealth models like this have expanded rapidly since the COVID-19 public health emergency relaxed prescribing rules, but those emergency flexibilities are being wound down by the DEA and HHS.

How Cash-Pay Telehealth Prescribing Works

Under current federal rules, a prescriber must conduct a legitimate patient-provider relationship before issuing a prescription. The DEA's 2023 proposed rule on telemedicine prescribing of controlled substances would require at minimum one in-person or real-time audio-visual visit for Schedule III-V drugs. GLP-1 agents such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not controlled substances, so the Ryan Haight Act does not apply directly. Still, the FDA's guidance on prescribing standards requires a documented clinical evaluation. Patients can read the current DEA telemedicine rulemaking at FDA.gov and the DEA diversion control division.

Why the Business Model Matters for Safety

Cash-pay models eliminate insurance prior-authorization hurdles, which can help patients access medically appropriate therapy faster. The trade-off: no insurer is independently reviewing whether the prescribing is appropriate. That shifts the entire safety burden to the platform's internal medical oversight. Patients should ask specifically who reviews clinical decisions, what specialty training that person holds, and whether a formal quality-assurance process exists.

Evaluating Willow's Physician Credentials

No telehealth platform's claims about its medical team can substitute for independent verification. Every state medical board maintains a free public lookup tool. Before starting any prescription program, check the prescribing physician's name against the relevant state board database.

What to Look for in a State Board Search

A clean record shows an active license, no disciplinary actions, no probationary conditions, and a board-certified specialty consistent with the treatment being offered. For GLP-1 weight-loss prescribing, relevant board certifications include internal medicine (ABIM), family medicine (ABFM), and obesity medicine (ABOM). The American Board of Obesity Medicine ABOM has certified over 7,000 physicians as of 2024, and its directory is publicly searchable.

Specialty Training and GLP-1 Prescribing

The 2023 American Association of Clinical Endocrinology (AACE) Consensus Statement on Obesity states: "Obesity is a chronic, relapsing, multifactorial disease that requires ongoing management by clinicians trained in its evaluation and treatment." [1] Prescribing semaglutide or tirzepatide without a structured obesity-management protocol, cardiovascular risk assessment, and follow-up plan falls below that standard. Ask Willow directly whether its prescribers have ABOM certification or equivalent fellowship training.

Medical Director Role

Legitimate telehealth platforms publish the name, credentials, and state licensure of their medical director. That person is accountable to state medical boards for the platform's prescribing culture. If Willow does not clearly name its medical director in its published materials, that is a red flag worth resolving before payment.

GLP-1 Evidence Base and Prescribing Standards

GLP-1 receptor agonists have the most rigorous weight-loss trial data of any drug class currently available. Understanding that evidence helps patients judge whether a telehealth platform's prescribing decisions are grounded in the published literature or driven primarily by sales volume.

STEP and SURMOUNT Trial Data

In STEP-1 (N=1,961), once-weekly semaglutide 2.4 mg subcutaneous produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). [2] In STEP-4 (N=803), patients who continued semaglutide maintained weight loss while those switched to placebo regained 6.9 percentage points of body weight by week 68. [3] Tirzepatide data from SURMOUNT-1 (N=2,539) showed 20.9% mean weight reduction at the 15 mg dose at 72 weeks versus 3.1% placebo (P<0.001). [4]

These are the trials Willow's clinical protocols should reference. If a platform's intake form does not screen for contraindications identified in those trials, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 (FDA boxed warning on semaglutide and tirzepatide labels), the prescribing is not guideline-concordant. [5]

FDA-Approved Indications and Off-Label Use

Wegovy (semaglutide 2.4 mg) received FDA approval for chronic weight management in June 2021 for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. [6] Zepbound (tirzepatide 2.5-15 mg) received FDA approval for the same indication in November 2023. [7] Prescribing outside those parameters is not automatically wrong, but it requires documented clinical justification in the patient record.

Cardiovascular Outcome Data

The SELECT trial (N=17,604) found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease (HR 0.80; 95% CI 0.72-0.90; P<0.001). [8] The FDA approved a cardiovascular risk-reduction indication for Wegovy in March 2024 based on these data. [9] A prescribing platform that does not assess cardiovascular history as part of intake is missing a clinically and now regulatory-relevant piece of the evaluation.

Compounded GLP-1 Medications: Legal and Safety Risks

Many cash-pay telehealth platforms, including those in Willow's category, have offered compounded semaglutide or tirzepatide as lower-cost alternatives to brand-name products. The FDA's legal and safety position on this practice has tightened considerably since 2024.

FDA Shortage Status and Compounding Legality

Compounding of a drug that appears on the FDA drug shortage list is permissible under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA removed branded tirzepatide (Zepbound) from its shortage list in December 2024 and set enforcement deadlines for compounders to wind down production. [10] Semaglutide's shortage status has been similarly contested. The FDA has issued multiple warning letters to compounders and telehealth platforms distributing compounded semaglutide that does not meet 503B standards. [11]

What 503A vs. 503B Means for Patients

A 503A pharmacy compounds for individual patients with a valid prescription. It is not subject to the same current Good Manufacturing Practice (cGMP) requirements as 503B outsourcing facilities. A 503B outsourcing facility registers with the FDA, undergoes inspection, and operates under cGMP. Patients receiving compounded GLP-1 products should ask whether the dispensing pharmacy is 503A or 503B, and they can verify 503B registration directly on the FDA's outsourcing facility database. [12]

Reported Adverse Events with Compounded Products

The FDA's MedWatch database has received adverse-event reports linked to compounded semaglutide, including reports of dosing errors associated with multi-dose vials that require patient self-measurement. [13] The agency stated in a 2024 safety communication: "FDA is aware of reports of adverse events, including hospitalizations, after patients used compounded semaglutide products." [14] Patients who experience adverse events from any Willow-prescribed product should report them directly to MedWatch at FDA MedWatch.

Women's Health Services and Hormonal Therapy Standards

Willow's stated scope includes women's hormonal health beyond GLP-1 therapy, which may encompass menopausal hormone therapy (MHT), contraception, and thyroid management.

Menopausal Hormone Therapy Guidelines

The Menopause Society (formerly NAMS) 2022 position statement concludes that hormone therapy remains the most effective treatment for vasomotor symptoms and that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." [15] Any telehealth platform prescribing MHT should screen for contraindications including estrogen-sensitive cancers, undiagnosed vaginal bleeding, active thromboembolic disease, and liver disease, as outlined in the FDA labeling for conjugated estrogens. [16]

Thyroid Function and Weight Management

Subclinical hypothyroidism affects approximately 4.3% of the U.S. Population per NHANES data, and overt hypothyroidism affects roughly 0.3%. [17] Weight gain is a common presenting complaint in both conditions. A GLP-1-prescribing platform that does not review recent thyroid-function tests before initiating semaglutide or tirzepatide risks attributing thyroid-driven weight gain to lifestyle factors, delaying appropriate treatment. Competent clinical intake should include a review of TSH results within the prior 12 months.

Contraception and Drug Interactions

GLP-1 receptor agonists slow gastric emptying, which may reduce the absorption of oral contraceptives. The Ozempic prescribing information notes this interaction and recommends that patients taking oral hormonal contraceptives switch to a non-oral method or add a barrier method for four weeks after each dose escalation. [18] A telehealth platform prescribing both GLP-1 agents and oral contraceptives to the same patient should document how this interaction is being managed.

How to Assess Whether Willow Is Legitimate

"Legit" in the telehealth context means different things to different stakeholders. From a regulatory standpoint, it means licensed, compliant, and dispensing through legally authorized channels. From a patient-safety standpoint, it means clinically rigorous, transparent, and responsive to complaints.

LegitScript Certification

LegitScript is a third-party verification service used by Google, Mastercard, and others to assess healthcare merchant compliance. Certification requires evidence of valid pharmacy licenses, prescriber credentials, and compliance with applicable laws. Patients can search any telehealth platform at LegitScript.com to check current certification status. A platform operating without LegitScript certification is not automatically non-compliant, but the absence is worth noting.

BBB Profile and Complaint History

The Better Business Bureau (BBB) maintains public complaint histories for enrolled businesses. Reviewing complaint themes for any telehealth platform reveals patterns that aggregate rating scores can obscure. Common complaint categories for GLP-1 telehealth platforms include billing disputes, difficulty canceling subscriptions, delayed medication shipments, and lack of clinician responsiveness. Check Willow's BBB profile at bbb.org and filter for complaints closed in the last 12 months.

State Attorney General and FTC Complaints

If a telehealth platform engages in deceptive billing, makes unsubstantiated efficacy claims, or fails to deliver promised services, patients can file complaints with their state attorney general's consumer protection division and with the Federal Trade Commission at reportfraud.ftc.gov. The FTC has taken enforcement action against multiple health and wellness subscription services in 2023 and 2024 for deceptive cancellation practices. [19]

Questions to Ask Before Enrolling

Ask Willow's customer service team for the following before paying:

1. The full name and state license number of the physician who will review your intake.
2. Whether that physician is board-certified and in what specialty.
3. The name and 503A/503B status of the fulfillment pharmacy.
4. The specific semaglutide or tirzepatide product (brand or compounded) and its source.
5. The cancellation and refund policy in writing.

If the platform cannot or will not answer those five questions before enrollment, consider that a signal about how it will respond to clinical concerns after enrollment.

Regulatory Compliance and Telehealth Law

State Medical Board Jurisdiction

Each state's medical board licenses and disciplines physicians practicing in that state, including those practicing via telehealth to patients located in that state. The Interstate Medical Licensure Compact (IMLC) allows expedited licensure across member states, but a compact license is still a state license. If a Willow physician prescribes to a patient in a state where that physician is not licensed, both the physician and the platform may face disciplinary action. Patients can verify IMLC participation status at imlcc.org.

FDA Oversight of Telehealth-Prescribed Drugs

The FDA does not directly regulate the practice of medicine, but it does regulate drugs, devices, and the pharmacies that dispense them. A telehealth platform dispensing adulterated, misbranded, or illegally compounded products is subject to FDA enforcement regardless of how it characterizes its business model. The FDA's Office of Criminal Investigations has opened cases against online pharmacies distributing unapproved GLP-1 products. [20]

HIPAA and Patient Data

Telehealth platforms handling protected health information (PHI) must comply with HIPAA's Privacy and Security Rules. Patients should review Willow's privacy policy specifically for language about sharing PHI with third-party marketers or data brokers, which is impermissible without explicit patient authorization under 45 CFR 164.508. [21]

Clinical Protocols: What Rigorous GLP-1 Telehealth Looks Like

The Obesity Medicine Association's 2023 clinical practice guidelines recommend that GLP-1 therapy be initiated at the lowest approved dose and titrated per the manufacturer's schedule, with monthly check-ins during the titration phase and quarterly visits during maintenance. [22] A platform following this standard should include:

• Documented BMI and weight-related comorbidity screening at intake.
• Cardiovascular history review consistent with SELECT-trial contraindications.
• Thyroid history review given the boxed warning on GLP-1 labels.
• Structured dose-titration schedule with clinician-reviewed check-ins.
• Clear protocol for managing nausea, vomiting, and injection-site reactions.
• A defined escalation path to in-person care if adverse events occur.

Platforms that offer a one-time intake with no structured follow-up do not meet this standard. The American Diabetes Association's 2024 Standards of Care in Diabetes specify that GLP-1 receptor agonists should be used "as part of a comprehensive management plan" that includes lifestyle intervention and ongoing monitoring. [23]